share_log

MannKind (NASDAQ:MNKD) Shares Gap Down After Earnings Miss

MannKind (NASDAQ:MNKD) Shares Gap Down After Earnings Miss

曼肯德(納斯達克代碼：MNKD)盈利低於預期後股價差距縮小
Defense World ·  2022/08/11 01:52

MannKind Co. (NASDAQ:MNKD – Get Rating)'s share price gapped down before the market opened on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $4.09, but opened at $3.95. MannKind shares last traded at $4.34, with a volume of 48,786 shares traded.

週三，在令人失望的財報公佈後，曼肯德公司(納斯達克代碼：MNKD-GET Rating)的股價在開盤前大幅下跌。該股此前收於4.09美元，開盤報3.95美元。曼肯德股票最新報4.34美元，總成交量為48,786股。

The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $18.90 million during the quarter, compared to analysts' expectations of $15.62 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. The firm's quarterly revenue was down 18.9% on a year-over-year basis.

這家生物製藥公司公佈了本季度每股收益(0.11美元)，低於普遍預期的(0.09美元)和(0.02美元)。該業務當季營收為1,890萬美元，高於分析師預期的1,562萬美元。在去年同一季度，該公司公佈了每股收益(0.05美元)。該公司季度營收同比下降18.9%。

Get
到達
MannKind
曼肯德
alerts:
警報：

Analyst Upgrades and Downgrades

分析師升級和下調評級

Separately, StockNews.com raised MannKind to a "sell" rating in a report on Saturday, April 30th.

另外，StockNews.com在4月30日星期六的一份報告中將MannKind的評級上調至“賣出”。

Institutional Trading of MannKind

MannKind的機構交易

Institutional investors and hedge funds have recently modified their holdings of the business. Oakworth Capital Inc. bought a new position in shares of MannKind during the 1st quarter valued at about $25,000. Northwestern Mutual Wealth Management Co. increased its position in shares of MannKind by 277.9% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 7,056 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 5,189 shares during the last quarter. Nisa Investment Advisors LLC bought a new position in shares of MannKind during the 2nd quarter valued at about $30,000. Russell Investments Group Ltd. bought a new position in shares of MannKind during the 4th quarter valued at about $39,000. Finally, International Assets Investment Management LLC bought a new position in shares of MannKind during the 1st quarter valued at about $39,000. Hedge funds and other institutional investors own 43.57% of the company's stock.
機構投資者和對衝基金最近調整了對該公司的持股。Oakworth Capital Inc.在第一季度購買了價值約25,000美元的MannKind新股頭寸。西北互惠財富管理公司在第二季度增持了277.9%的曼肯德股票。西北互惠財富管理公司目前持有7,056股這家生物製藥公司的股票，價值27,000美元，該公司在上個季度又購買了5,189股。NISA Investment Advisors LLC在第二季度購買了價值約3萬美元的MannKind新股頭寸。羅素投資集團(Russell Investments Group Ltd.)在第四季度購買了價值約3.9萬美元的MannKind新股頭寸。最後，國際資產投資管理公司在第一季度購買了價值約3.9萬美元的MannKind股票的新頭寸。對衝基金和其他機構投資者持有該公司43.57%的股份。

MannKind Stock Performance

MannKind股票表現

The stock has a market capitalization of $1.08 billion, a P/E ratio of -11.59 and a beta of 1.75. The firm has a 50-day moving average price of $3.94 and a 200 day moving average price of $3.68.

該股市值為10.8億美元，市盈率為-11.59，貝塔係數為1.75。該公司的50日移動均線價格為3.94美元，200日移動均線價格為3.68美元。

About MannKind

關於曼肯德

(Get Rating)

(獲取評級)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.

MannKind公司是一家生物製藥公司，在美國專注於內分泌和孤兒肺部疾病吸入性治療產品的開發和商業化。它提供Afrezza，一種吸入型胰島素，用於改善成人糖尿病患者的血糖控制。它還向成人和兒童內分泌學家以及其他治療甲狀腺功能減退症的醫療保健提供者推廣胸腺功能。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on MannKind (MNKD)
  • Could Rite Aid Be an Acquisition Target, Again?
  • The How And Why of Investing in Oil Stocks
  • The How and Why of Investing in Gold Stocks
  • Workhorse Group Is Ready To Get Back On The Horse
  • A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
  • 免費獲取StockNews.com關於MannKind的研究報告(MNKD)
  • Rite Aid會再次成為收購目標嗎？
  • 投資石油股票的方式和原因
  • 投資黃金股票的方式和原因
  • 工作馬集團準備重返賽馬
  • DraftKings，Inc.的圓底開始逆轉

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.

接受《MannKind Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對MannKind和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論